There have been many randomised clinical trials to assess the cardiovascular outcomes of SGLT-2 inhibitors (empagliflozin, canagliflozin and dapagliflozin), including the Canagliflozin Cardiovascular Assessment Study (CANVAS), the Dapagliflozin Effect on Cardiovascular Events Thrombosis in Myocardial Infarction 58 (DECLARE—TIMI 58) and the Empagliflozin Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients (EMPA-REG OUTCOME) [13,14,15,16,17,18,19,20,23,24]. The gene discussed is SLC5A2; the disease is type 2 diabetes mellitus.